Targeting CD39 with therapeutic antibodies to enhance extracellular ATP signaling is a promising approach for cancer treatment and is expected to produce synergistic effects, ultimately resulting in improved tumor suppression when used in combination with chemotherapeutic agents that induce ATP release or PD-1/PD-L1 checkpoint inhibitors. Here, PDCD1 is linked to neoplasm.